<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJA</journal-id>
<journal-id journal-id-type="hwp">spaja</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Alzheimers Dis Other Demen</journal-id>
<journal-title>American Journal of Alzheimer's Disease &amp; Other Dementias®</journal-title>
<issn pub-type="ppub">1533-3175</issn>
<issn pub-type="epub">1938-2731</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1533317512467681</article-id>
<article-id pub-id-type="publisher-id">10.1177_1533317512467681</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Progress in Frontotemporal Dementia Research</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xinling</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff1-1533317512467681">1</xref>
<xref ref-type="aff" rid="aff2-1533317512467681">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Yuedi</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-1533317512467681">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Wei</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff1-1533317512467681">1</xref>
<xref ref-type="aff" rid="aff2-1533317512467681">2</xref>
<xref ref-type="corresp" rid="corresp1-1533317512467681"/>
</contrib>
</contrib-group>
<aff id="aff1-1533317512467681">
<label>1</label>Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China</aff>
<aff id="aff2-1533317512467681">
<label>2</label>Key Laboratory of Medical Neurobiology of Chinese Ministry of Health, Hangzhou, China</aff>
<aff id="aff3-1533317512467681">
<label>3</label>Center for Cognition and Brain Disorders &amp; The Affiliated Hospital, Hangzhou Normal University School, Hangzhou, China</aff>
<author-notes>
<corresp id="corresp1-1533317512467681">Wei Chen, BS, Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, East Qingchun Road 3, Hangzhou, Zhejiang 310016, China. Email: <email>srrcw@zju.edu.cn</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>1</issue>
<fpage>15</fpage>
<lpage>23</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Frontotemporal dementia (FTD) is the second most common type of presenile dementia and is the most common form of dementia with the onset before 60 years of age. Its typical symptoms include behavioral disorders, affective symptoms, and language disorders. The FTD is a genetically and pathologically heterogeneous degenerative disorder. Animal models have provided more insights into the pathogenic mechanisms. There are currently no medications that are specifically approved for the treatment of FTD by the Food and Drug Administration. In this article, we review the recent advances in the molecular pathogenesis, pathology, animal models, and therapy for FTD. Better understanding of the pathogenesis and the use of animal models will help develop novel therapeutic strategies and provide new targets for FTD treatment.</p>
</abstract>
<kwd-group>
<kwd>frontotemporal dementia</kwd>
<kwd>Alzheimer’s</kwd>
<kwd>pathology</kwd>
<kwd>genetics</kwd>
<kwd>animal models</kwd>
<kwd>therapy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1533317512467681">
<title>Introduction</title>
<p>Frontotemporal dementia (FTD) is an insidious, progressive neurodegenerative disease. It is the second most common dementia with presenile onset, after Alzheimer’s disease (AD), and accounts for 5% to 15% of all types of dementia.<sup>
<xref ref-type="bibr" rid="bibr1-1533317512467681">1</xref>,<xref ref-type="bibr" rid="bibr2-1533317512467681">2</xref>
</sup> It is a costly disease, both in terms of personal suffering and economic loss. The 3 typical clinical syndromes of FTD include behavioral, emotional, and language disorders.<sup>
<xref ref-type="bibr" rid="bibr3-1533317512467681">3</xref>
</sup> Patients with FTD typically present with symptoms including personality changes, impulsivity, psychiatric disorders, hyperthymia or apathy, and overactivity. It encompasses a range of clinical syndromes such as behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SD), corticobasal syndrome (CBS), progressive nonfluent aphasia (PNFA), and a range of different pathologies.<sup>
<xref ref-type="bibr" rid="bibr4-1533317512467681">4</xref>
</sup> Each subtype of FTD includes some significant syndromes. Specifically, some patients of bvFTD become apathetic and social withdrawn, or oppositely others can become disinhibited and perform some inappropriate acts such as sexual or criminal behaviors. Patients of SD have trouble in naming and semantic understanding, but are intact with word pronunciation and speech fluency. In contrast, patients of PNFA have inability to articulation but without trouble in word comprehension. Patients of CBS have difficulties in movement, but differentiate diagnosis with Parkinson disease and progressive supranuclear palsy (PSP) is needed. The clinical presentations of FTD differ from those of AD. In the early stages of FTD, patients typically present with personality and behavioral changes, including impulsivity, disinhibition, executive dysfunction, and language abnormalities. In contrast to patients of AD, patients of FTD usually perform relatively well in visuospatial ability and memory tasks.<sup>
<xref ref-type="bibr" rid="bibr5-1533317512467681">5</xref>
</sup> As the clinical manifestations overlap with other psychiatric disorders such as personality disorders, affective disorders, and AD, FTD is often misdiagnosed.</p>
<p>In this article, we use FTD as general term for the clinical syndromes and frontotemporal lobe degeneration (FTLD) for the associated pathologies. Here, we review the recent research progress in the molecular genetics, pathology, animal models, and therapy of FTD.</p>
</sec>
<sec id="section2-1533317512467681">
<title>Molecular Genetics</title>
<p>Frontotemporal dementia is a genetically and pathologically heterogeneous degenerative disorder.<sup>
<xref ref-type="bibr" rid="bibr6-1533317512467681">6</xref>,<xref ref-type="bibr" rid="bibr7-1533317512467681">7</xref>
</sup> Approximately one-third to one-half of the FTD cases are caused by gene mutations,<sup>
<xref ref-type="bibr" rid="bibr8-1533317512467681">8</xref>
</sup> but the majority are sporadic without a definite known cause. There are many pathogenic genes related to FTD. Mutations in the genes of microtubule-associated protein tau (<italic>MAPT</italic>), progranulin (<italic>PGRN</italic> or <italic>GRN</italic>), and <italic>C9ORF72</italic> have been shown as the major causes of FTD. Minority of cases are caused by mutations in 4 other genes: valosin-containing protein (<italic>VCP</italic>), TAR DNA-binding protein 43 (<italic>TARDBP</italic>), chromatin-modifying protein 2B (<italic>CHMP2B</italic>), and fused in sarcoma (<italic>FUS</italic>). In addition, an involvement of apolipoprotein E (<italic>apoE)</italic> gene locus in the genetics of FTD has been reported.<sup>
<xref ref-type="bibr" rid="bibr9-1533317512467681">9</xref>
</sup>
</p>
<sec id="section3-1533317512467681">
<title>Microtubule-Associated Protein Tau</title>
<p>The <italic>MAPT</italic> gene lies on chromosome 17q21.1. The major function of tau is to stimulate the microtubule assembly and to maintain the microtubule structure, which is crucial to maintaining the integrity of nerves and axoplasmic transport. The <italic>MAPT</italic> gene has been shown to contain 2 extended haplotypes, termed as H1 and H2. The H2 haplotype is associated with the appearance of clinical symptoms in carriers at a relatively earlier age and with a dramatic decline in glucose utilization in the frontal brain areas.<sup>
<xref ref-type="bibr" rid="bibr10-1533317512467681">10</xref>
</sup> Altered metabolism of tau protein affects its interactions with tubulin, leading to destabilization of the microtubule structure and initiating the generation of toxic tau aggregates and may be a cause of FTD.<sup>
<xref ref-type="bibr" rid="bibr11-1533317512467681">11</xref>
</sup>
</p>
<p>It has been shown that cerebral spinal fluid (CSF) levels of tau are abnormal and amyloid-β peptide (1-42) levels are decreased in patients of FTD.<sup>
<xref ref-type="bibr" rid="bibr12-1533317512467681">12</xref>
</sup> Distinguishing features of patients with tau-positive FTD include visual perceptual–spatial difficulties and extrapyramidal disorders, and these are observed more frequently than in other patients of FTD. These patients have relatively significant cortical atrophy in the frontal and parietal regions as shown by magnetic resonance imaging (MRI), and the pathology in these regions is obvious. Patients with tau-negative FTD are also distinguished by their greater difficulties on social intercourse, language, and executive functions. This is accompanied by significant cortical atrophy in the frontal and temporal regions and significant frontal and temporal pathology.<sup>
<xref ref-type="bibr" rid="bibr13-1533317512467681">13</xref>
</sup>
</p>
</sec>
<sec id="section4-1533317512467681">
<title>Progranulin</title>
<p>Progranulin is encoded by a single gene on chromosome 17q21. Loss-of-function mutations in the <italic>PGRN</italic> gene have been identified as a monogenic cause of FTLD.<sup>
<xref ref-type="bibr" rid="bibr14-1533317512467681">14</xref>
<xref ref-type="bibr" rid="bibr15-1533317512467681"/>–<xref ref-type="bibr" rid="bibr16-1533317512467681">16</xref>
</sup> In patients of FTLD with ubiquitinated inclusions (FTLD-U), there are mutations in the gene coding for PGRN.<sup>
<xref ref-type="bibr" rid="bibr14-1533317512467681">14</xref>-<xref ref-type="bibr" rid="bibr15-1533317512467681">15</xref>
</sup> Davion et al suggest that PGRN mutations may also occur in apparently sporadic FTD-U cases.<sup>
<xref ref-type="bibr" rid="bibr17-1533317512467681">17</xref>
</sup> Chiang et al reported that <italic>PGRN</italic> mutations may be one of the causes of FTD in the Karolinska family.<sup>
<xref ref-type="bibr" rid="bibr18-1533317512467681">18</xref>
</sup> It has been reported that haplo insufficiency of <italic>PGRN</italic> resulting from <italic>PGRN</italic> gene mutations is one of the predominant mechanisms leading to FTD.<sup>
<xref ref-type="bibr" rid="bibr19-1533317512467681">19</xref>,<xref ref-type="bibr" rid="bibr20-1533317512467681">20</xref>
</sup> And recently suberoylanilide hydroxamic acid, a Food and Drug Administration (FDA)-approved histone deacetylase inhibitor, has been identified as an enhancer of <italic>PGRN</italic> expression.<sup>
<xref ref-type="bibr" rid="bibr21-1533317512467681">21</xref>
</sup> It has demonstrated therapeutic potential in other neurodegenerative diseases and thus holds promise as a first-generation drug for the prevention and treatment of FTD.</p>
<p>Recently, there is evidence provided by Bossu et al that circulating interleukin (IL)-6 is increased in the <italic>PGRN</italic>-mutated patients of FTD when compared to both patients of <italic>PGRN</italic> nonmutated FTD and controls.<sup>
<xref ref-type="bibr" rid="bibr22-1533317512467681">22</xref>
</sup> They concluded that the profile of circulating proinflammatory cytokines is altered in PGRN-related symptomatic FTD. Thus, IL-6 is as a possible specific mediator and a potential therapeutic target in this monogenic disease.</p>
<p>In addition, patients with FTD with <italic>PGRN</italic> mutations have a faster rate of whole brain atrophy than patients of FTD with <italic>MAPT </italic>mutations, but similar rates of hippocampal atrophy.<sup>
<xref ref-type="bibr" rid="bibr23-1533317512467681">23</xref>
</sup> Neuroimaging studies show that <italic>PGRN</italic> and <italic>MAPT</italic> mutations have distinct patterns of atrophy—asymmetric fronto-temporo-parietal atrophy with PGRN versus relatively symmetric medial temporal and orbitofrontal lobe atrophy with <italic>MAPT</italic> mutations.<sup>
<xref ref-type="bibr" rid="bibr24-1533317512467681">24</xref>
</sup>
</p>
</sec>
<sec id="section5-1533317512467681">
<title>C9ORF72 Gene</title>
<p>DeJesus-Hernandez et al<sup>
<xref ref-type="bibr" rid="bibr25-1533317512467681">25</xref>
</sup> reported an expansion of a noncoding GGGGCC hexanucleotide repeat in the gene <italic>C9ORF72</italic> that is strongly associated with the disease in a large FTD/amyotrophic lateral sclerosis (ALS) kindred, previously reported to be conclusively linked to chromosome 9p. Their findings indicate that repeat expansion in <italic>C9ORF72</italic> might be a major cause of both FTD and ALS. This view was supported by Renton et al.<sup>
<xref ref-type="bibr" rid="bibr26-1533317512467681">26</xref>
</sup> They found that a large proportion of apparently unrelated familial ALS and FTD cases carried the same hexanucleotide repeat expansion within C9ORF72. This repeat expansion segregates perfectly with the disease in the Finnish population, underlying 46.0% of familial ALS and 21.1% of sporadic ALS in that population. Taken together with the D90A superoxide dismutase 1 (<italic>SOD1</italic>) mutation, 87% of familial ALS in Finland is now explained by the simple monogenic cause. The repeat expansion is also present in one-third of familial ALS cases of outbred European descent, making it the most common genetic cause of these fatal neurodegenerative diseases identified to date. These studies demonstrate that a massive hexanucleotide repeat expansion within <italic>C9ORF72</italic> is the cause of chromosome 9p21-linked ALS, FTD, and ALS-FTD. Recently, it was reported that the <italic>C9ORF72</italic> gene mutation was associated with patterns of atrophy, predominantly frontal lobe atrophy, with involvement of the anterior temporal, parietal lobes, and cerebellum.<sup>
<xref ref-type="bibr" rid="bibr27-1533317512467681">27</xref>
</sup> This specific pattern differed from that observed in <italic>MAPT</italic> and <italic>GRN</italic> mutations and sporadic behavioral variant of FTD.</p>
</sec>
<sec id="section6-1533317512467681">
<title>Valosin-Containing Protein</title>
<p>The VCP is a member of the AAA-ATPase gene superfamily and functions as a molecular chaperone in a plethora of distinct cellular activities, including ubiquitin-dependent, endoplasmic-reticulum-associated protein degradation, stress responses, programmed cell death, membrane fusion, nuclear envelope reconstruction, and postmitotic Golgi reassembly. Many of these activities are directly or indirectly regulated by the ubiquitin proteasome system (UPS).<sup>
<xref ref-type="bibr" rid="bibr28-1533317512467681">28</xref>,<xref ref-type="bibr" rid="bibr29-1533317512467681">29</xref>
</sup> The <italic>VCP</italic> gene mutations can cause inclusion body myopathy, Paget’s disease of the bone, and FTD.<sup>
<xref ref-type="bibr" rid="bibr30-1533317512467681">30</xref>
</sup> However, the mechanisms by which VCP mutations cause neurodegeneration and TAR DNA-binding protein 43 (TDP-43) accumulation are unclear.</p>
</sec>
<sec id="section7-1533317512467681">
<title>TAR DNA-Binding Protein 43</title>
<p>The TDP-43, which is encoded by the <italic>TARDBP</italic> gene located on chromosome 1, is the major pathological protein in FTLD-U.<sup>
<xref ref-type="bibr" rid="bibr31-1533317512467681">31</xref>
<xref ref-type="bibr" rid="bibr32-1533317512467681"/>
<xref ref-type="bibr" rid="bibr33-1533317512467681"/>–<xref ref-type="bibr" rid="bibr34-1533317512467681">34</xref>
</sup> The TDP-43 continuously shuttles between the nucleus and the cytoplasm. This process is partially regulated by nuclear localization signals and nuclear export signals.<sup>
<xref ref-type="bibr" rid="bibr35-1533317512467681">35</xref>,<xref ref-type="bibr" rid="bibr36-1533317512467681">36</xref>
</sup> The TDP-43 manages the regulation of transcription and splicing and is a neuronal activity-responsive factor functioning in the regulation of neuronal plasticity.<sup>
<xref ref-type="bibr" rid="bibr37-1533317512467681">37</xref>
</sup> In addition, it is involved in other cellular processes such as apoptosis, cell division, micro RNA biogenesis, and messenger RNA stabilization.<sup>
<xref ref-type="bibr" rid="bibr38-1533317512467681">38</xref>,<xref ref-type="bibr" rid="bibr39-1533317512467681">39</xref>
</sup> The loss of normal TDP-43 function may contribute to the pathogenesis of FTLD.<sup>
<xref ref-type="bibr" rid="bibr39-1533317512467681">39</xref>
</sup>
</p>
</sec>
<sec id="section8-1533317512467681">
<title>The <italic>FUS</italic> Gene</title>
<p>The <italic>FUS</italic> gene, on chromosome 16, was originally identified as a component of fusion oncogenes in a variety of human cancers.<sup>
<xref ref-type="bibr" rid="bibr40-1533317512467681">40</xref>
</sup> It encodes FUS protein, which is a ubiquitously expressed,<sup>
<xref ref-type="bibr" rid="bibr41-1533317512467681">41</xref>
</sup> multifunctional, DNA/RNA-binding protein that shares striking functional homology with TDP-43.<sup>
<xref ref-type="bibr" rid="bibr42-1533317512467681">42</xref>,<xref ref-type="bibr" rid="bibr43-1533317512467681">43</xref>
</sup> The FUS is a highly conserved ribonucleoprotein that mainly resides in the nucleus while shuttling between the cytoplasm and the nucleus,<sup>
<xref ref-type="bibr" rid="bibr44-1533317512467681">44</xref>,<xref ref-type="bibr" rid="bibr45-1533317512467681">45</xref>
</sup> but in neurons and glia, it has a predominant nuclear localization.<sup>
<xref ref-type="bibr" rid="bibr41-1533317512467681">41</xref>
</sup> The normal physiological role of FUS in the brain is not completely understood, but it may be involved in neuronal plasticity and the maintenance of dendritic integrity.<sup>
<xref ref-type="bibr" rid="bibr46-1533317512467681">46</xref>,<xref ref-type="bibr" rid="bibr47-1533317512467681">47</xref>
</sup> The FUS has recently been linked to both ALS and FTLD.<sup>
<xref ref-type="bibr" rid="bibr42-1533317512467681">42</xref>,<xref ref-type="bibr" rid="bibr48-1533317512467681">48</xref>
</sup> The FUS inclusions are seen in the brains of many FTD cases (FTLD-FUS).<sup>
<xref ref-type="bibr" rid="bibr4-1533317512467681">4</xref>,<xref ref-type="bibr" rid="bibr49-1533317512467681">49</xref>
</sup>
</p>
</sec>
<sec id="section9-1533317512467681">
<title>Chromatin-Modifying Protein 2B</title>
<p>The first <italic>CHMP2B</italic> mutation was identified in a large Danish FTLD family<sup>
<xref ref-type="bibr" rid="bibr50-1533317512467681">50</xref>
</sup> and the second mutation was subsequently identified in a Belgian patient with familial FTLD.<sup>
<xref ref-type="bibr" rid="bibr51-1533317512467681">51</xref>
</sup> These mutations lead to C-terminal truncation of the CHMP2B protein. Animal models of the <italic>CHMP2B</italic> gene mutations have been generated and will be discussed below.</p>
</sec>
</sec>
<sec id="section10-1533317512467681">
<title>Pathology</title>
<p>The neuropathology of FTLD syndromes is heterogeneous. The 2 major pathologies are FTLD-tau and FTLD-TDP, which are characterized by tau or TDP-43 positive inclusions, respectively.<sup>
<xref ref-type="bibr" rid="bibr4-1533317512467681">4</xref>,<xref ref-type="bibr" rid="bibr52-1533317512467681">52</xref>
</sup> The FUS-positive inclusions have recently been described in a subset of FTLD cases<sup>
<xref ref-type="bibr" rid="bibr53-1533317512467681">53</xref>,<xref ref-type="bibr" rid="bibr54-1533317512467681">54</xref>
</sup> and 2 rare neuropathological subtypes remain, those with ubiquitin-positive inclusions that are negative for tau, TDP-43, and FUS, termed FTLD-UPS<sup>
<xref ref-type="bibr" rid="bibr49-1533317512467681">49</xref>
</sup> (primarily <italic>CHMP2B</italic> mutation cases) and those with no discernable inclusions, termed FTLD-ni.<sup>
<xref ref-type="bibr" rid="bibr49-1533317512467681">49</xref>
</sup> The nomenclature for FTLD has been updated (<xref ref-type="table" rid="table1-1533317512467681">Table 1</xref>).<sup>
<xref ref-type="bibr" rid="bibr49-1533317512467681">49</xref>
</sup>
</p>
<table-wrap id="table1-1533317512467681" position="float">
<label>Table 1.</label>
<caption>
<p>Nomenclature for Frontotemporal Lobar Degeneration (Mackenzie et al<sup><xref ref-type="bibr" rid="bibr49-1533317512467681">49</xref></sup>).</p>
</caption>
<graphic alternate-form-of="table1-1533317512467681" xlink:href="10.1177_1533317512467681-table1.tif"/>
<table>
<thead>
<tr>
<th align="center" colspan="2">2010 Recommendation<hr/></th>
</tr>
<tr>
<th>Major Molecular Class</th>
<th>Recognized Subtype<sup><xref ref-type="table-fn" rid="table-fn2-1533317512467681">a</xref></sup>
</th>
<th>Associated Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTLD-tau</td>
<td>PiD</td>
<td>
<italic>MAPT</italic>
</td>
</tr>
<tr>
<td>
</td>
<td>CBD</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>PSP</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>AGD</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>MSTD</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>NFT-dementia</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>WMT-GGI</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>Unclassifiable</td>
<td>
</td>
</tr>
<tr>
<td>FTLD-TDP</td>
<td>Types 1-4</td>
<td>
<italic>GRN</italic>
</td>
</tr>
<tr>
<td>
</td>
<td>Unclassifiable</td>
<td>
<italic>VCP</italic>
</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>
<italic>9p</italic>
</td>
</tr>
<tr>
<td>
</td>
<td>
</td>
<td>(<italic>TARDBP</italic>)<sup><xref ref-type="table-fn" rid="table-fn3-1533317512467681">b</xref></sup>
</td>
</tr>
<tr>
<td>FTLD-UPS</td>
<td>FTD-3</td>
<td>
<italic>CHMP2B</italic>
</td>
</tr>
<tr>
<td>FTLD-FUS</td>
<td>aFTLD-U</td>
<td>(<italic>FUS</italic>)<sup><xref ref-type="table-fn" rid="table-fn4-1533317512467681">c</xref></sup>
</td>
</tr>
<tr>
<td>
</td>
<td>NIFID</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>BIBD</td>
<td>
</td>
</tr>
<tr>
<td>FTLD-ni</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1533317512467681">
<p>Abbreviations: aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitinated inclusions; AGD, argyrophilic grain disease; BIBD, basophilic inclusion body disease; CBD, corticobasal degeneration; CHMP2B, charged multivescicular body protein 2B; FTD-3, frontotemporal dementia linked to chromosome 3; FTLD, frontotemporal lobar degeneration; FUS, fused in sarcoma; GRN, progranulin gene; IFs, intermediate filaments; MAPT, microtubule-associated protein tau; MSTD, multiple system tauopathy with dementia; NFT-dementia, neurofibrillary tangle predominant dementia; ni, no inclusions; NIFID, neuronal intermediate filament inclusion disease; PiD, Pick’s disease; PSP, progressive supranuclear palsy; TARDBP, transactive response DNA binding protein; TDP, TAR DNA-binding protein 43; UPS, ubiquitin proteasome system; VCP, valosin containing protein; WMT-GGI, white matter tauopathy with globular glial inclusions; 9p, genetic locus on chromosome 9p linked to familial amyotrophic lateral sclerosis and frontotemporal dementia.</p>
</fn>
<fn id="table-fn2-1533317512467681">
<p>
<sup>a</sup> Indicates the characteristic pattern of pathology, not the clinical syndrome. Note that FTDP-17 is not listed as a pathological subtype because cases with different MAPT mutations do not have a consistent pattern of pathology. These cases would all be FTLD-tau, but further subtyping would vary.</p>
</fn>
<fn id="table-fn3-1533317512467681">
<p>
<sup>b</sup> Rare case reports of patients with clinical FTD and TDP-43 pathology associated with TARDBP genetic variants.</p>
</fn>
<fn id="table-fn4-1533317512467681">
<p>
<sup>c</sup> One patient reported with a FUS mutation and FTD/ALS clinical phenotype but no description of pathology.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Josephs et al have observed severe caudate atrophy at autopsy in FTLD-FUS, and they hold the view that one of the most characteristic features of FTLD-FUS is severe caudate atrophy, identified on gross and microscopic examination.<sup>
<xref ref-type="bibr" rid="bibr55-1533317512467681">55</xref>,<xref ref-type="bibr" rid="bibr56-1533317512467681">56</xref>
</sup> Caudate atrophy on MRI appears to be significantly greater in FTLD-FUS compared to FTLD-TDP and FTLD-TAU, suggesting that severe caudate atrophy may be a useful clinical feature to predict FTLD-FUS pathology.<sup>
<xref ref-type="bibr" rid="bibr57-1533317512467681">57</xref>
</sup>
</p>
<p>A significant decrease in sAβPPβ, Aβ<sub>38</sub>, and Aβ<sub>40</sub> levels in CSF is found in FTD.<sup>
<xref ref-type="bibr" rid="bibr58-1533317512467681">58</xref>
</sup> Significant changes in amyloid biomarkers, particularly for Aβ<sub>38</sub>, are therefore seen in FTD and that can be considered as a potential biomarker to differentiate FTD. Thus, this could be quite useful for diagnostic purposes and might provide additional evidence on the interrelationship between Tau and AβPP biology.</p>
</sec>
<sec id="section11-1533317512467681">
<title>Animal Models</title>
<p>Animal models are useful in dissecting the pathogenic mechanisms and offer a valuable technique for further investigations into FTD. Here, we summarize several types of animal models reported in recent years.</p>
<sec id="section12-1533317512467681">
<title>The FUS Transgenic Rats</title>
<p>Mutant FUS transgenic rats have been recently generated.<sup>
<xref ref-type="bibr" rid="bibr59-1533317512467681">59</xref>
</sup> These rats developed progressive paralysis secondary to degeneration of motor axons and displayed a substantial loss of neurons in the cortex and the hippocampus. This neuronal loss is accompanied by ubiquitin aggregation and glial reactivation in the brain. Although transgenic rats that overexpressed the wild-type human FUS were asymptomatic at young ages, they show a deficit in spatial learning and memory and a significant loss of cortical and hippocampal neurons at advanced ages. These results suggest that mutant FUS is more toxic to neurons than normal FUS and that increased expression of normal FUS is sufficient to induce neuronal death. The FUS transgenic rats reproduced some phenotypes of ALS and FTLD and will provide a useful model for mechanistic studies of FUS-related diseases.</p>
</sec>
<sec id="section13-1533317512467681">
<title>The CHMP2B Transgenic Mice and CHMP2B Knockout Mice</title>
<p>Ghazi-Noori et al<sup>
<xref ref-type="bibr" rid="bibr60-1533317512467681">60</xref>
</sup> generated the first mouse model of CHMP2B-induced neurodegeneration and showed that expression of mutant CHMP2B<sup>intron5</sup> leads to striking neurodegenerative changes that were not observed in CHMP2B<sup>wild-type </sup>transgenics or CHMP2B knockout mice. Their studies have provided evidence in favor of a gain-of-function mechanism for CHMP2B-induced FTLD by showing neuropathology mimicking human patients only in the CHMP2B<sup>intron 5</sup> mice and not in the CHMP2B<sup>wild-type</sup> mice or Chmp2b knockout mice. They also identify axonal changes as an early degenerative feature in the CHMP2B<sup>intron 5</sup> mice, suggesting a potential role for altered axonal function in the disease process. The generation of this CHMP2B<sup>intron5</sup> mouse model has provided new insight into the mechanisms by which mutant CHMP2B leads to neuronal dysfunction in vivo.</p>
</sec>
<sec id="section14-1533317512467681">
<title>Mouse Models of PGRN-Deficient FTLD</title>
<p>It has been reported that certain aspects of PGRN-deficient FTLD can be modeled in the mouse (Grn<sup>−/−</sup>).<sup>
<xref ref-type="bibr" rid="bibr61-1533317512467681">61</xref>
</sup> Large number of activated microglia and astrocytes are accumulated in the brains of aged Grn<sup>−/− </sup>mice.<sup>
<xref ref-type="bibr" rid="bibr8-1533317512467681">8</xref>,<xref ref-type="bibr" rid="bibr62-1533317512467681">62</xref>
</sup> Abnormal microgliosis and astrogliosis can be detected as early as 7 months of age, the same age at which social behavior abnormalities are first observable. Also by this time, abnormal intracellular accumulations of ubiquitinated autofluorescent lipid–protein aggregates called lipofuscin, which are by-products of failed proteolysis, begin to be seen in the Grn<sup>−/− </sup>neurons.<sup>
<xref ref-type="bibr" rid="bibr63-1533317512467681">63</xref>
</sup> However, the Grn<sup>−/−</sup> mice do not develop significant cytoplasmic accumulations of TDP-43. This model will provide an important platform for understanding the pathophysiology of FTLD and the basic biology of PGRN in the brain.</p>
<p>Loss-of-function mutations in the <italic>PGRN</italic> gene were recently identified as the cause of tau-negative, ubiquitin-positive FTD.<sup>
<xref ref-type="bibr" rid="bibr14-1533317512467681">14</xref>-<xref ref-type="bibr" rid="bibr15-1533317512467681">15</xref>
</sup> Subsequently, PGRN-deficient mice were used to investigate the role of PGRN in FTD. In this model, the mice display behavioral deficits in social recognition and depression- and anxiety-like behaviors. Moreover, these mice develop cognitive deficits that progress with aging. These deficits are associated with neuropathological changes, such as accumulation of ubiquitin and cytosolic phosphorylated TDP-43 in the hippocampus.<sup>
<xref ref-type="bibr" rid="bibr62-1533317512467681">62</xref>
</sup>
</p>
</sec>
<sec id="section15-1533317512467681">
<title>P301L Tau Mice</title>
<p>The expression of human FTD mutant P301L tau has been reported to reproduce tau aggregation and neurofibrillary tangle formation in mice.<sup>
<xref ref-type="bibr" rid="bibr64-1533317512467681">64</xref>,<xref ref-type="bibr" rid="bibr65-1533317512467681">65</xref>
</sup> These tau transgenic models of FTD have shown that FTDP-17 mutations accelerate tau aggregation and cause neuronal dysfunction and loss in vivo. Furthermore, the tau transgenic mice model has important aspects of FTD, such as PSP and corticobasal degeneration, through the exhibition of glial pathology that affects neuronal function and thus the manifestation of these behavioral symptoms.<sup>
<xref ref-type="bibr" rid="bibr66-1533317512467681">66</xref>
</sup>
</p>
<p>A novel research approach has incorporated a single mutation, which is homologous to the common FTDP-17T P301L mutation, directly into the endogenous mouse gene. The “P301L” tau knockin mouse model mimics the human disease.<sup><xref ref-type="bibr" rid="bibr67-1533317512467681">67</xref>.</sup>In contrast to existing transgenic mouse models that overexpress human P301L mutant tau, no overt tau pathology develops during the normal life span of the knockin mice. This model may therefore represent the earliest pathological alterations caused by tau dysfunction.</p>
<p>The models described above have provided powerful tools for our further understanding of relevant human diseases. However, they may not accurately reproduce the anatomical distribution of the lesions in the human brain. The mouse models are thought to be superior to the invertebrates in studying memory and motor functions in consideration of neuroanatomy and the endocrine system. However, recent work in invertebrate species highlights the advantages in dissecting signaling pathways, performing modifier screenings and analyzing families of mutations in parallel.</p>
</sec>
<sec id="section16-1533317512467681">
<title>K3 Mice Model for Human FTD With the K369I Mutation</title>
<p>The K3 mice, a transgenic mouse strain which is reported to express human tau carrying the FTD mutation K369I, not only model histopathological characteristics of FTD with the K369I tau mutation but also models memory impairment, amyotrophy, and Parkinsonism. The K3 mice provide a unique model for aspects of Pick’s disease, but are mainly used to explore FTD-associated Parkinsonism and memory impairment.<sup>
<xref ref-type="bibr" rid="bibr68-1533317512467681">68</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section17-1533317512467681">
<title>Therapy</title>
<p>There has been considerably less research focusing on the treatment of FTD than that of AD. There are currently no FDA-approved medications specifically indicated for the treatment of FTD.<sup>
<xref ref-type="bibr" rid="bibr69-1533317512467681">69</xref>
</sup> At present, several pharmacological approaches, such as antidepressants, antipsychotics, anticholinesterase agents, and memantine, have been widely used clinically in order to control the specific symptoms of FTD. López-Pousa et al<sup>
<xref ref-type="bibr" rid="bibr70-1533317512467681">70</xref>
</sup> performed a cross-sectional design using 1092 cases with AD and 64 cases with FTLD registered by the Registry of Dementias of Girona. They found that 43.8% of the patients of FTLD took antidementia drug, 31.3% of the patients of FTLD used antipsychotics, 1.6% of the patients of FTLD used anti-Parkinson drug, and 53.1% of the patients took antidepressants. However, they concluded a discrepancy regarding clinical practice and the recommendations based upon clinical evidence. On the whole, it does not mean that there is little effect on drug treatment. Specifically, antidepressants and antipsychotics mainly appear to improve behavioral symptoms of FTD including irritability, agitation, depressive symptoms, and eating disorders.<sup>
<xref ref-type="bibr" rid="bibr71-1533317512467681">71</xref>
<xref ref-type="bibr" rid="bibr72-1533317512467681"/>
<xref ref-type="bibr" rid="bibr73-1533317512467681"/>
<xref ref-type="bibr" rid="bibr74-1533317512467681"/>–<xref ref-type="bibr" rid="bibr75-1533317512467681">75</xref>
</sup> Anticholinesterases and memantine have been widely used in the treatment of AD. Acetylcholinesterase inhibitors (AChEIs) can improve the cognitive performance, activities of daily living, behavioral symptoms, and executive function as well as visual attention.<sup>
<xref ref-type="bibr" rid="bibr76-1533317512467681">76</xref>
<xref ref-type="bibr" rid="bibr77-1533317512467681"/>–<xref ref-type="bibr" rid="bibr78-1533317512467681">78</xref>
</sup> They can also reduce the worsening of clinical AD symptoms.<sup>
<xref ref-type="bibr" rid="bibr79-1533317512467681">79</xref>
</sup> However, AChE inhibitors were not found effective or even can worsen the disinhibition and compulsions rather than exert a beneficial effect in patients with FTD.<sup>
<xref ref-type="bibr" rid="bibr80-1533317512467681">80</xref>
<xref ref-type="bibr" rid="bibr81-1533317512467681"/>–<xref ref-type="bibr" rid="bibr82-1533317512467681">82</xref>
</sup> Memantine, a more recent AD drug, shows significant benefits on cognitive abilities and global functioning.<sup>
<xref ref-type="bibr" rid="bibr83-1533317512467681">83</xref>
</sup> Some studies have also shown that it can improve the language function<sup>
<xref ref-type="bibr" rid="bibr84-1533317512467681">84</xref>
</sup> and may help alleviate the behavioral symptoms.<sup>
<xref ref-type="bibr" rid="bibr85-1533317512467681">85</xref>
</sup> As to FTD, the efficacy of memantine is relatively positive.</p>
<sec id="section18-1533317512467681">
<title>Antidepressant and Antipsychotics</title>
<p>Studies of antidepressant medications for FTD have mainly been focused on serotonin selective reuptake inhibitors (SSRIs), trazodone, and atypical antipsychotic drugs.</p>
<sec id="section19-1533317512467681">
<title>The SSRIs</title>
<p>The recovery of the serotoninergic system may play an important role in the effective treatment of FTD.<sup>
<xref ref-type="bibr" rid="bibr86-1533317512467681">86</xref>
</sup> The SSRIs (including fluoxetine, sertraline, and paroxetine) appear to improve the behavioral symptoms<sup>
<xref ref-type="bibr" rid="bibr71-1533317512467681">71</xref>-<xref ref-type="bibr" rid="bibr72-1533317512467681">72</xref>
</sup> and decrease the disinhibition impulsivity, repetitive behaviors, and eating disorders in FTD.<sup>
<xref ref-type="bibr" rid="bibr73-1533317512467681">73</xref>
</sup> However, little evidence for a curative effect on the cognitive symptoms has been found.<sup>
<xref ref-type="bibr" rid="bibr71-1533317512467681">71</xref>
</sup> Ishikawa et al described 2 patients with FTD with compulsive complaints of pain.<sup>
<xref ref-type="bibr" rid="bibr87-1533317512467681">87</xref>
</sup> Fluvoxamine markedly improved their complaints of pain as well as other typical symptoms. Fluvoxamine may be effective in addressing behavioral disturbances due to an improvement in serotoninergic dysfunction in the frontal medial and cingulate cortices. It may also be effective in managing compulsive complaints of pain as a result of improvement in compulsive symptoms and exaggerated reactions to pain in FTD or, alternatively, of the analgesic effect of the SSRI. Moretti et al conducted an open-label, randomized, uncontrolled study.<sup>
<xref ref-type="bibr" rid="bibr88-1533317512467681">88</xref>
</sup> Patients aged 64 to 68 years with a diagnosis of FTD were randomized to receive paroxetine up to 20 mg/d (n = 8) or piracetam up to 1200 mg/d (n = 8). At 14 months, the patients treated with paroxetine showed significant improvements in behavioral symptoms and the side effects were easily tolerable and there were no dropouts. However, Deakin et al reported conflicting findings based on a double-blind, placebo-controlled crossover trial in 10 patients with FTD.<sup>
<xref ref-type="bibr" rid="bibr89-1533317512467681">89</xref>
</sup> Doses of paroxetine were progressively increased to 40 mg daily and the same regimen was used for placebo capsules. All participants were assessed using a battery of cognitive tests in the sixth week following the onset of treatment. At each assessment, caregivers were interviewed using the Neuropsychiatric Inventory (NPI) to assess delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, and aberrant motor behavior. The Cambridge Behavioral Inventory (CBI) was also used to assess the changes in behavior, personality, mood, memory, orientation, and activities of daily living. The results showed that there were no significant differences in either the NPI or the CBI scores between the 2 groups. However, paroxetine caused a decrease in accuracy in paired associates learning, reversal learning, and delayed pattern recognition. Thus, in opposition to the view of Moretti et al, the researchers reported that a chronic course of paroxetine may selectively impair the aspects of cognitive function. The discrepancy in the results of the above 2 studies may be due to the differences in the participants studied. For example, some patients with advanced FTD may have severe depletion of the 5-hydroxytryptamine (5-HT) receptor-containing neurons and declining paroxetine’s effects. The discrepancy could also be due to procedural and methodological differences including drug selection and dose differences.</p>
</sec>
<sec id="section20-1533317512467681">
<title>Trazodone</title>
<p>At present, most studies on trazodone have confirmed that trazodone has a positive effect in patients with FTD. It appears to be an effective treatment for the behavioral symptoms including irritability, agitation, depressive symptoms, and eating disorders. In addition, it can moderately control the clinical severity,<sup>
<xref ref-type="bibr" rid="bibr73-1533317512467681">73</xref>,<xref ref-type="bibr" rid="bibr90-1533317512467681">90</xref>
</sup> although results from the Mini-Mental State Examination have not shown significant improvement between pre- and posttreatment. There are 2 major shortcomings in these studies, namely small sample sizes and inconsistent evidence for improvement. Further investigation with a larger cohort is needed to reveal the efficacy. Whether trazodone may act by modulating the function of 5-HT system and the corresponding receptors also warrants future studies.</p>
</sec>
<sec id="section21-1533317512467681">
<title>Antipsychotics</title>
<p>Antipsychotics, such as aripiprazole and olanzapine, can improve the clinical symptoms of FTD such as behavioral disturbances and irritability.<sup>
<xref ref-type="bibr" rid="bibr73-1533317512467681">73</xref>
<xref ref-type="bibr" rid="bibr74-1533317512467681"/>–<xref ref-type="bibr" rid="bibr75-1533317512467681">75</xref>
</sup> Unfortunately, they may also cause side effects, such as somnolence, weight gain, Parkinson’s symptoms, and increase susceptibility to extrapyramidal side effects,<sup>
<xref ref-type="bibr" rid="bibr91-1533317512467681">91</xref>
</sup> which limit their therapeutic use.</p>
</sec>
</sec>
<sec id="section22-1533317512467681">
<title>Anticholinesterases and Memantine</title>
<p>Due to the efficacy of cholinesterase inhibitors and memantine for AD, their use for treating bvFTD is common, despite the lack of strong evidence to support such treatment.<sup>
<xref ref-type="bibr" rid="bibr92-1533317512467681">92</xref>
</sup> Because no drugs specific for treating FTD are currently available, AD drugs are commonly used for improving the clinical outcome of patients with FTD.</p>
<sec id="section23-1533317512467681">
<title>Cholinesterase inhibitors</title>
<p>The pathophysiology of FTD and AD is somewhat different. It has been confirmed that the acetylcholine system appears to be relatively intact in patients with FTD.<sup>
<xref ref-type="bibr" rid="bibr71-1533317512467681">71</xref>,<xref ref-type="bibr" rid="bibr93-1533317512467681">93</xref>,<xref ref-type="bibr" rid="bibr94-1533317512467681">94</xref>
</sup> Di Lazzaro et al used short latency afferent inhibition of the motor cortex to examine the function of central cholinergic circuits. Dysfunction of the central cholinergic circuits was observed in AD but not in FTD.<sup>
<xref ref-type="bibr" rid="bibr95-1533317512467681">95</xref>
</sup> The issue of whether cholinesterase inhibitors may be effective in the treatment of FTD has caused concern among researchers. Rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, was reported to improve the behavioral impairment and reduce the caregiver burden of patients with FTD.<sup>
<xref ref-type="bibr" rid="bibr96-1533317512467681">96</xref>
</sup> However, donepezil, another AChE inhibitor, was found to worsen disinhibition and compulsions rather than exert a beneficial effect.<sup>
<xref ref-type="bibr" rid="bibr80-1533317512467681">80</xref>
</sup> It has been confirmed that galantamine, also an AChE inhibitor, is not effective in bvFTD, although a trend for efficacy was found in primary progressive aphasia.<sup>
<xref ref-type="bibr" rid="bibr55-1533317512467681">55</xref>
</sup> A recent study reported that significant brain cholinergic deficits are not seen in FTD by [<sup>
<xref ref-type="bibr" rid="bibr11-1533317512467681">11</xref>
</sup>C] <italic>N</italic>-methylpiperidin-4-yl acetate positron emission tomography.<sup>
<xref ref-type="bibr" rid="bibr97-1533317512467681">97</xref>
</sup> This finding may explain the unresponsiveness of patients with FTD to cholinergic modulation therapy.</p>
</sec>
<sec id="section24-1533317512467681">
<title>Memantine</title>
<p>As has been discovered from recent AD drug studies, memantine may function not only as an antagonist of <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors but also as an inhibitor to block the expression of amyloid precursor protein and tau,<sup>
<xref ref-type="bibr" rid="bibr98-1533317512467681">98</xref>
</sup> reducing the levels of insoluble amyloid-β, total tau, and hyperphosphorylated tau.<sup>
<xref ref-type="bibr" rid="bibr99-1533317512467681">99</xref>
</sup> It is under evaluation to ascertain efficacy in treating FTD.<sup>
<xref ref-type="bibr" rid="bibr73-1533317512467681">73</xref>
</sup> Some studies have indicated that patients with FTD show significant improvements in NPI scores after the treatment with memantine,<sup>
<xref ref-type="bibr" rid="bibr100-1533317512467681">100</xref>
</sup> especially in the subscale scores of apathy, agitation, and anxiety.<sup>
<xref ref-type="bibr" rid="bibr101-1533317512467681">101</xref>
</sup> Furthermore, memantine is well tolerated in patients. However, Diehl-Schmid et al conducted a single-center, open, uncontrolled study with memantine treatment of 16 outpatients with a diagnosis of FTD for a duration of 6 months.<sup>
<xref ref-type="bibr" rid="bibr102-1533317512467681">102</xref>
</sup> Behavior, executive function as well as activities of daily living and extrapyramidal motor symptoms remained unchanged during the trial. The first double-blind, placebo-controlled study of memantine in bvFTD with 49 cases followed up for 12 months indicates that memantine (10 mg twice a day) appeared to be safe and was well-tolerated in these patients but did not improve bvFTD.<sup>
<xref ref-type="bibr" rid="bibr103-1533317512467681">103</xref>
</sup> As memantine is well-tolerated, a further multicenter trial with larger sample sizes is needed to verify the above results.</p>
</sec>
</sec>
</sec>
<sec id="section25-1533317512467681">
<title>Conclusions and Future Directions</title>
<p>Although approximately one-third to one-half of the FTD cases are caused by gene mutations, the exact pathogenesis of the majority FTLD is still unclear. There is currently no evidence-based effective treatment for FTD. The few clinical trials conducted so far had relatively small sample sizes and were rarely controlled studies. Furthermore, the conclusions of drug efficacy drawn from these studies are conflicting. Fortunately, evidence relating to neural and biochemical changes lends support to the investigations of antidepressants and the explorations of other new drugs. Molecular and genetic studies, especially studies targeting tau protein, TDP-43 and FUS, may provide feasible avenues in developing effective treatments or even cure for FTLD. Exploring novel animal models may offer valuable methodologies for further investigations into FTD and challenge current hypotheses. Meanwhile, more large-scale, placebo-controlled trials are needed to explore the efficacy of currently available symptomatic treatments for FTD. If successful, such studies will have the benefit of providing evidence-based clinical treatment recommendations for currently available drugs.</p>
<p>Despite the recent advancements, there are multiple questions that remain unanswered. Is there a common pathophysiologial mechanism that underlies the different forms of hereditary FTLD-U and FTLD-tau? Does the aggregation of 1 protein trigger other disease processes (such as Alzheimer’s disease and Lewy body disorder) with the corresponding protein deposition? Can the development of novel biomarker assays help diagnosis and differential diagnosis of FTD? As our knowledge of FTD develops, clinicians should be aware of the large variation in onset age and the wide clinical spectrum of symptoms. At the same time, a revised clinical criterion based on an international large-scale study is needed. It will be much beneficial if the new clinical criterion can incorporate the pathophysiology and the clinical features of FTD.</p>
<p>Future scientific efforts should emphasize on the 3 key directions. First, explore biomarkers that can be examined in clinical laboratories to support the diagnosis and differential diagnosis of FTD. Second, renew attempts should be made to develop animal models that imitate the progression of FTD, different stages of the disease, and the various spectrums. Finally, based on these efforts in elucidating the pathophysiology, an emphasis must focus on the development of effective therapeutic interventions for FTD.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1533317512467681">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1533317512467681">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the Key Project of the Department of Science and Technology of Zhejiang Province (No. 2007C13053), from the Key Program of Natural Science Foundation of Zhejiang Province (No. Z2100133), and from the Supported by Program for Changjiang Scholars and Innovative Research Team in University (No. IRT1038) to Dr. W.Chen, and the Science and Technology Programme of Hangzhou Municipality (No. 20100633B08) to Dr Y. Shen. </p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1533317512467681">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bird</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>VanSwieten</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Epidemiology and genetics of frontotemporal dementia/Pick's disease</article-title>. <source>Ann Neurol</source>. <year>2003</year>;<volume>54</volume>(<issue>Suppl 5</issue>):<fpage>S29</fpage>–<lpage>S31</lpage>.</citation>
</ref>
<ref id="bibr2-1533317512467681">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Hsiung</surname>
<given-names>GY</given-names>
</name>
<etal/>
</person-group> <article-title>A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results</article-title>. <source>Neuroepidemiology</source>. <year>2003</year>;<volume>22</volume>(<issue>5</issue>):<fpage>265</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr3-1533317512467681">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL.</given-names>
</name>
</person-group> <article-title>Clinical features of frontotemporal dementia</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2005</year>;(<issue>19 suppl 1</issue>):<fpage>S3</fpage>–<lpage>S6</lpage>.</citation>
</ref>
<ref id="bibr4-1533317512467681">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>EH</given-names>
</name>
<etal/>
</person-group> <article-title>Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations</article-title>. <source>Acta Neuropathol</source>. <year>2009</year>;<volume>117</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr5-1533317512467681">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harciarek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jodzio</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review</article-title>. <source>Neuropsychol Rev</source>. <year>2005</year>;<volume>15</volume>(<issue>3</issue>):<fpage>131</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr6-1533317512467681">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments</article-title>. <source>Neurogenetics</source>. <year>2007</year>;<volume>8</volume>(<issue>4</issue>):<fpage>237</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr7-1533317512467681">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Genetics of frontotemporal lobar degeneration</article-title>. <source>Front Neurol</source>. <year>2012</year>;<volume>3</volume>:<fpage>52</fpage>.</citation>
</ref>
<ref id="bibr8-1533317512467681">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>YF</given-names>
</name>
<etal/>
</person-group> <article-title>Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging</article-title>. <source>Am J Pathol</source>. <year>2010</year>;<volume>177</volume>(<issue>1</issue>):<fpage>311</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr9-1533317512467681">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seripa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bizzarro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Panza</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>The APOE gene locus in frontotemporal dementia and primary progressive aphasia</article-title>. <source>Arch Neurol</source>. <year>2011</year>;<volume>68</volume>(<issue>5</issue>):<fpage>622</fpage>–<lpage>628</lpage>.</citation>
</ref>
<ref id="bibr10-1533317512467681">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laws</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Perneczky</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Drzezga</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia</article-title>. <source>Am J Psychiatry</source>. <year>2007</year>;<volume>164</volume>(<issue>10</issue>):<fpage>1577</fpage>–<lpage>1584</lpage>.</citation>
</ref>
<ref id="bibr11-1533317512467681">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kowalska</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)</article-title>. <source>Postepy Hig Med Dosw (Online)</source>. <year>2009</year>;<volume>63</volume>(<issue>278-286</issue>).</citation>
</ref>
<ref id="bibr12-1533317512467681">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gloeckner</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Meyne</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia</article-title>. <source>J Alzheimers Dis</source>. <year>2008</year>;<volume>14</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr13-1533317512467681">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Libon</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>MS</given-names>
</name>
<etal/>
</person-group> <article-title>Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia</article-title>. <source>Arch Neurol</source>. <year>2007</year>;<volume>64</volume>(<issue>11</issue>):<fpage>1601</fpage>–<lpage>1609</lpage>.</citation>
</ref>
<ref id="bibr14-1533317512467681">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Pickering-Brown</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group> <article-title>Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17</article-title>. <source>Nature</source>. <year>2006</year>;<volume>442</volume>(<issue>7105</issue>):<fpage>916</fpage>–<lpage>919</lpage>.</citation>
</ref>
<ref id="bibr15-1533317512467681">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruts</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gijselinck</surname>
<given-names>I</given-names>
</name>
<name>
<surname>van der Zee</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21</article-title>. <source>Nature</source>. <year>2006</year>;<volume>442</volume>(<issue>7105</issue>):<fpage>920</fpage>–<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr16-1533317512467681">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Archetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alberici</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series</article-title>. <source>Neurogenetics</source>. <year>2008</year>;<volume>9</volume>(<issue>3</issue>):<fpage>197</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr17-1533317512467681">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Clinicopathologic correlation in PGRN mutations</article-title>. <source>Neurology</source>. <year>2007</year>;<volume>69</volume>(<issue>11</issue>):<fpage>1113</fpage>–<lpage>1121</lpage>.</citation>
</ref>
<ref id="bibr18-1533317512467681">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiang</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Rosvall</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brohede</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family</article-title>. <source>Alzheimers Dement</source>. <year>2008</year>;<volume>4</volume>(<issue>6</issue>):<fpage>414</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr19-1533317512467681">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gijselinck</surname>
<given-names>I</given-names>
</name>
<name>
<surname>van der Zee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Progranulin locus deletion in frontotemporal dementia</article-title>. <source>Hum Mutat</source>. <year>2008</year>;<volume>29</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr20-1533317512467681">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Bekris</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group> <article-title>The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration</article-title>. <source>Arch Neurol</source>. <year>2010</year>;<volume>67</volume>(<issue>2</issue>):<fpage>161</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr21-1533317512467681">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cenik</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sephton</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Dewey</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group>, <article-title>Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia</article-title>. <source>J Biol Chem</source>. <year>2011</year>;<volume>286</volume>(<issue>18</issue>):<fpage>16101</fpage>–<lpage>16108</lpage>.</citation>
</ref>
<ref id="bibr22-1533317512467681">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bossu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Salani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Alberici</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients</article-title>. <source>J Neuroinflammation</source>. <year>2011</year>;<volume>8</volume>:<fpage>65</fpage>.</citation>
</ref>
<ref id="bibr23-1533317512467681">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Weigand</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Gunter</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group> <article-title>Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN</article-title>. <source>Neurology</source>. <year>2011</year>;<volume>77</volume>(<issue>4</issue>):<fpage>393</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr24-1533317512467681">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohrer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>Phenotypic signatures of genetic frontotemporal dementia</article-title>. <source>Curr Opin Neurol</source>. <year>2011</year>;<volume>24</volume>(<issue>6</issue>):<fpage>542</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr25-1533317512467681">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeJesus-Hernandez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<etal/>
</person-group> <article-title>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS</article-title>. <source>Neuron</source>. <year>2011</year>;<volume>72</volume>(<issue>2</issue>):<fpage>245</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr26-1533317512467681">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renton</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Majounie</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Waite</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD</article-title>. <source>Neuron</source>. <year>2011</year>;<volume>72</volume>(<issue>2</issue>):<fpage>257</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr27-1533317512467681">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Weigand</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<etal/>
</person-group> <article-title>Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics</article-title>. <source>Brain</source>. <year>2012</year>;<volume>135</volume>(<issue>pt 3</issue>):<fpage>794</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr28-1533317512467681">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimonis</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Fulchiero</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vesa</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder</article-title>. <source>Biochim Biophys Acta.</source> <year>2008</year>;<volume>1782</volume>(<issue>12</issue>):<fpage>744</fpage>–<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr29-1533317512467681">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guinto</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Ritson</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>JP</given-names>
</name>
<etal/>
</person-group> <article-title>Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy</article-title>. <source>Acta Neuropathol</source>. <year>2007</year>;<volume>114</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr30-1533317512467681">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watts</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Wymer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kovach</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group> <article-title>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein</article-title>. <source>Nat Genet</source>. <year>2004</year>;<volume>36</volume>(<issue>4</issue>):<fpage>377</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr31-1533317512467681">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liscic</surname>
<given-names>RM</given-names>
</name>
</person-group>. <article-title>Frontotemporal dementias: update on recent developments in molecular genetics and neuropathology</article-title>. <source>Arh Hig Rada Toksikol</source>. <year>2009</year>;<volume>60</volume>(<issue>1</issue>):<fpage>117</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr32-1533317512467681">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<etal/>
</person-group> <article-title>Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43</article-title>. <source>Acta Neuropathol.</source> <year>2007</year>;<volume>113</volume>(<issue>5</issue>):<fpage>521</fpage>–<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr33-1533317512467681">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sampathu</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>LK</given-names>
</name>
<etal/>
</person-group> <article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title>. <source>Science</source>. <year>2006</year>;<volume>314</volume>(<issue>5796</issue>):<fpage>130</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr34-1533317512467681">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwong</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sampathu</surname>
<given-names>DM</given-names>
</name>
<etal/>
</person-group> <article-title>TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease</article-title>. <source>Acta Neuropathol</source>. <year>2007</year>;<volume>114</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr35-1533317512467681">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winton</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Igaz</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group> <article-title>Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation</article-title>. <source>J Biol Chem</source>. <year>2008</year>;<volume>283</volume>(<issue>19</issue>):<fpage>13302</fpage>–<lpage>13309</lpage>.</citation>
</ref>
<ref id="bibr36-1533317512467681">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayala</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Zago</surname>
<given-names>P</given-names>
</name>
<name>
<surname>D'Ambrogio</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Structural determinants of the cellular localization and shuttling of TDP-43</article-title>. <source>J Cell Sci</source>. <year>2008</year>;<volume>121</volume>(<issue>pt 22</issue>):<fpage>3778</fpage>–<lpage>3785</lpage>.</citation>
</ref>
<ref id="bibr37-1533317512467681">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HY</given-names>
</name>
<etal/>
</person-group> <article-title>TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor</article-title>. <source>J Neurochem</source>. <year>2008</year>;<volume>105</volume>(<issue>3</issue>):<fpage>797</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr38-1533317512467681">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tolnay</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
</person-group>. <article-title>The molecular basis of frontotemporal dementia</article-title>. <source>Expert Rev Mol Med</source>. <year>2009</year>;<volume>11</volume>:<fpage>e23</fpage>.</citation>
</ref>
<ref id="bibr39-1533317512467681">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strong</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Volkening</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein</article-title>. <source>Mol Cell Neurosci</source>. <year>2007</year>;<volume>35</volume>(<issue>2</issue>):<fpage>320</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr40-1533317512467681">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riggi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cironi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Suva</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group> <article-title>Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET</article-title>. <source>J Pathol.</source> <year>2007</year>;<volume>213</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr41-1533317512467681">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersson</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Stahlberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arvidsson</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response</article-title>. <source>BMC Cell Biol.</source> <year>2008</year>;<volume>9</volume>:<fpage>37</fpage>.</citation>
</ref>
<ref id="bibr42-1533317512467681">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagier-Tourenne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>Rethinking ALS: the FUS about TDP-43</article-title>. <source>Cell</source>. <year>2009</year>;<volume>136</volume>(<issue>6</issue>):<fpage>1001</fpage>–<lpage>1004</lpage>.</citation>
</ref>
<ref id="bibr43-1533317512467681">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warraich</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>GA</given-names>
</name>
<etal/>
</person-group> <article-title>Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2010</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1408</fpage>–<lpage>1411</lpage>.</citation>
</ref>
<ref id="bibr44-1533317512467681">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zinszner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sok</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Immanuel</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling</article-title>. <source>J Cell Sci</source>. <year>1997</year>;<volume>110</volume>(<issue>pt 15</issue>):<fpage>1741</fpage>–<lpage>1750</lpage>.</citation>
</ref>
<ref id="bibr45-1533317512467681">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group> <article-title>Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription</article-title>. <source>Nature</source>. <year>2008</year>;<volume>454</volume>(<issue>7200</issue>):<fpage>126</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr46-1533317512467681">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujii</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Urushido</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology</article-title>. <source>Curr Biol</source>. <year>2005</year>;<volume>15</volume>(<issue>6</issue>):<fpage>587</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr47-1533317512467681">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujii</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Takumi</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines</article-title>. <source>J Cell Sci</source>. <year>2005</year>;<volume>118</volume>(<issue>pt 24</issue>):<fpage>5755</fpage>–<lpage>5765</lpage>.</citation>
</ref>
<ref id="bibr48-1533317512467681">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanson</surname>
<given-names>NA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Pandey</surname>
<given-names>UB</given-names>
</name>
</person-group>. <article-title>FUS-related proteinopathies: lessons from animal models</article-title>. <source>Brain Res</source>. <year>2012</year>;<volume>1462</volume>:<fpage>44</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr49-1533317512467681">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>EH</given-names>
</name>
<etal/>
</person-group> <article-title>Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update</article-title>. <source>Acta Neuropathol</source>. <year>2010</year>;<volume>119</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr50-1533317512467681">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skibinski</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Parkinson</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia</article-title>. <source>Nat Genet</source>. <year>2005</year>;<volume>37</volume>(<issue>8</issue>):<fpage>806</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr51-1533317512467681">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Zee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Urwin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro</article-title>. <source>Hum Mol Genet</source>. <year>2008</year>;<volume>17</volume>(<issue>2</issue>):<fpage>313</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr52-1533317512467681">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cairns</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>IR</given-names>
</name>
<etal/>
</person-group> <article-title>Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration</article-title>. <source>Acta Neuropathol</source>. <year>2007</year>;<volume>114</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr53-1533317512467681">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rademakers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Roeber</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>A new subtype of frontotemporal lobar degeneration with FUS pathology</article-title>. <source>Brain</source>. <year>2009</year>;<volume>132</volume>(<issue>pt 11</issue>):<fpage>2922</fpage>–<lpage>2931</lpage>.</citation>
</ref>
<ref id="bibr54-1533317512467681">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seelaar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Klijnsma</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>de Koning</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration</article-title>. <source>J Neurol.</source> <year>2010</year>;<volume>257</volume>(<issue>5</issue>):<fpage>747</fpage>–<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr55-1533317512467681">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions</article-title>. <source>Acta Neuropathol</source>. <year>2008</year>;<volume>116</volume>(<issue>2</issue>):<fpage>159</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr56-1533317512467681">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rossor</surname>
<given-names>MN</given-names>
</name>
<etal/>
</person-group> <article-title>Neurofilament inclusion body disease: a new proteinopathy?</article-title> <source>Brain</source>. <year>2003</year>;<volume>126</volume>(<issue>pt 10</issue>):<fpage>2291</fpage>–<lpage>2303</lpage>.</citation>
</ref>
<ref id="bibr57-1533317512467681">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group> <article-title>Caudate atrophy on MRI is a characteristic feature of FTLD-FUS</article-title>. <source>Eur J Neurol</source>. <year>2010</year>;<volume>17</volume>(<issue>7</issue>):<fpage>969</fpage>–<lpage>975</lpage>.</citation>
</ref>
<ref id="bibr58-1533317512467681">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabelle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Geny</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia</article-title>. <source>J Alzheimers Dis.</source> <year>2011</year>;<volume>26</volume>(<issue>3</issue>):<fpage>553</fpage>–<lpage>563</lpage>.</citation>
</ref>
<ref id="bibr59-1533317512467681">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration</article-title>. <source>PLoS Genet</source>. <year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e1002011</fpage>.</citation>
</ref>
<ref id="bibr60-1533317512467681">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghazi-Noori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Froud</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Mizielinska</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice</article-title>. <source>Brain</source>. <year>2012</year>;<volume>135</volume>(<issue>pt 3</issue>):<fpage>819</fpage>–<lpage>832</lpage>.</citation>
</ref>
<ref id="bibr61-1533317512467681">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
</person-group>. <article-title>Potential mechanisms of progranulin-deficient FTLD</article-title>. <source>J Mol Neurosci</source>. <year>2011</year>;<volume>45</volume>(<issue>3</issue>):<fpage>574</fpage>–<lpage>582</lpage>.</citation>
</ref>
<ref id="bibr62-1533317512467681">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dumont</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia</article-title>. <source>FASEB J</source>. <year>2010</year>;<volume>24</volume>(<issue>12</issue>):<fpage>4639</fpage>–<lpage>4647</lpage>.</citation>
</ref>
<ref id="bibr63-1533317512467681">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunk</surname>
<given-names>UT</given-names>
</name>
<name>
<surname>Terman</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Lipofuscin: mechanisms of age-related accumulation and influence on cell function</article-title>. <source>Free Radic Biol Med</source>. <year>2002</year>;<volume>33</volume>(<issue>5</issue>):<fpage>611</fpage>–<lpage>619</lpage>.</citation>
</ref>
<ref id="bibr64-1533317512467681">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McGowan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rockwood</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein</article-title>. <source>Nat Genet</source>. <year>2000</year>;<volume>25</volume>(<issue>4</issue>):<fpage>402</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr65-1533317512467681">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gotz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>van Dorpe</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils</article-title>. <source>Science</source>. <year>2001</year>;<volume>293</volume>(<issue>5534</issue>):<fpage>1491</fpage>–<lpage>1495</lpage>.</citation>
</ref>
<ref id="bibr66-1533317512467681">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gotz</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Tau and transgenic animal models</article-title>. <source>Brain Res Brain Res Rev</source>. <year>2001</year>;<volume>35</volume>(<issue>3</issue>):<fpage>266</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr67-1533317512467681">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Seereeram</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a “P301L” tau knockin mouse</article-title>. <source>Neurobiol Aging</source>. <year>2012</year>;<volume>33</volume>(<issue>3</issue>):<fpage>621</fpage>.</citation>
</ref>
<ref id="bibr68-1533317512467681">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ittner</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Fath</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>YD</given-names>
</name>
<etal/>
</person-group> <article-title>Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2008</year>;<volume>105</volume>(<issue>41</issue>):<fpage>15997</fpage>–<lpage>16002</lpage>.</citation>
</ref>
<ref id="bibr69-1533317512467681">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
</person-group>. <article-title>Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2007</year>;<volume>21</volume>(<issue>4</issue>):<fpage>S79</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr70-1533317512467681">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Pousa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Calvo-Perxas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lejarreta</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Use of antidementia drugs in frontotemporal lobar degeneration</article-title>. <source>Am J Alzheimers Dis Other Demen</source>. <year>2012</year>;<volume>27</volume>(<issue>4</issue>):<fpage>260</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr71-1533317512467681">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huey</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Putnam</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Grafman</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>66</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr72-1533317512467681">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swartz</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Lesser</surname>
<given-names>IM</given-names>
</name>
<etal/>
</person-group> <article-title>Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors</article-title>. <source>J Clin Psychiatry</source>. <year>1997</year>;<volume>58</volume>(<issue>5</issue>):<fpage>212</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr73-1533317512467681">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez</surname>
<given-names>MF</given-names>
</name>
</person-group>. <article-title>Frontotemporal dementia: therapeutic interventions</article-title>. <source>Front Neurol Neurosci</source>. <year>2009</year>;<volume>24</volume>:<fpage>168</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr74-1533317512467681">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fellgiebel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Hiemke</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism</article-title>. <source>World J Biol Psychiatry</source>. <year>2007</year>;<volume>8</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr75-1533317512467681">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Antonello</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group> <article-title>Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients</article-title>. <source>Am J Alzheimers Dis Other Demen</source>. <year>2003</year>;<volume>18</volume>(<issue>4</issue>):<fpage>205</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr76-1533317512467681">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doody</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Cholinesterase inhibitors and memantine: best practices</article-title>. <source>CNS Spectr</source>. <year>2008</year>;<volume>13</volume>(<issue>10 suppl 16</issue>):<fpage>34</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr77-1533317512467681">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daiello</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Festa</surname>
<given-names>EK</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease</article-title>. <source>J Clin Psychopharmacol</source>. <year>2010</year>;<volume>30</volume>(<issue>3</issue>):<fpage>245</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr78-1533317512467681">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prvulovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hampel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pantel</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Galantamine for Alzheimer's disease</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2010</year>;<volume>6</volume>(<issue>3</issue>):<fpage>345</fpage>–<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr79-1533317512467681">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkinson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schindler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schwam</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2009</year>;<volume>28</volume>(<issue>3</issue>):<fpage>244</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr80-1533317512467681">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Shapira</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>McMurtray</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2007</year>;<volume>15</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr81-1533317512467681">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kertesz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morlog</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Light</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Galantamine in frontotemporal dementia and primary progressive aphasia</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2008</year>;<volume>25</volume>(<issue>2</issue>):<fpage>178</fpage>–<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr82-1533317512467681">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Brien</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology</article-title>. <source>J Psychopharmacol</source>. <year>2011</year>;<volume>25</volume>(<issue>8</issue>):<fpage>997</fpage>–<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr83-1533317512467681">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mecocci</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bladstrom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stender</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2009</year>;<volume>24</volume>(<issue>5</issue>):<fpage>532</fpage>–<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr84-1533317512467681">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferris</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ihl</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients</article-title>. <source>Alzheimers Dement</source>. <year>2009</year>;<volume>5</volume>(<issue>5</issue>):<fpage>369</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr85-1533317512467681">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grossberg</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Pejovic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group> <article-title>Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2009</year>;<volume>27</volume>(<issue>2</issue>):<fpage>164</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr86-1533317512467681">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franceschi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anchisi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pelati</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group> <article-title>Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration</article-title>. <source>Ann Neurol</source>. <year>2005</year>;<volume>57</volume>(<issue>2</issue>):<fpage>216</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr87-1533317512467681">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shimomura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Stereotyped behaviors and compulsive complaints of pain improved by fluvoxamine in two cases of frontotemporal dementia</article-title>. <source>Seishin Shinkeigaku Zasshi</source>. <year>2006</year>;<volume>108</volume>(<issue>10</issue>):<fpage>1029</fpage>–<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr88-1533317512467681">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Antonello</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group> <article-title>Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study</article-title>. <source>Eur Neurol.</source> <year>2003</year>;<volume>49</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr89-1533317512467681">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deakin</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nestor</surname>
<given-names>PJ</given-names>
</name>
<etal/>
</person-group> <article-title>Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2004</year>;<volume>172</volume>(<issue>4</issue>):<fpage>400</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr90-1533317512467681">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lebert</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stekke</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hasenbroekx</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Frontotemporal dementia: a randomised, controlled trial with trazodone</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2004</year>;<volume>17</volume>(<issue>4</issue>):<fpage>355</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr91-1533317512467681">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pijnenburg</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group> <article-title>Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2003</year>;<volume>18</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr92-1533317512467681">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Off-label medication use in frontotemporal dementia</article-title>. <source>Am J Alzheimers Dis Other Demen</source>. <year>2010</year>;<volume>25</volume>(<issue>2</issue>):<fpage>128</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr93-1533317512467681">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alonso-Navarro</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jabbour-Wadih</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ayuso-Peralta</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>The neurochemistry and neuropharmacology of frontotemporal dementia</article-title>. <source>Rev Neurol</source>. <year>2006</year>;<volume>42</volume>(<issue>9</issue>):<fpage>556</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr94-1533317512467681">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Procter</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Qurne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>PT.</given-names>
</name>
</person-group> <article-title>Neurochemical features of frontotemporal dementia</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>1999</year>;(<issue>10 suppl 1</issue>):<fpage>80</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr95-1533317512467681">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Lazzaro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pilato</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dileone</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>66</volume>(<issue>7</issue>):<fpage>1111</fpage>–<lpage>1113</lpage>.</citation>
</ref>
<ref id="bibr96-1533317512467681">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Antonello</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group> <article-title>Rivastigmine in frontotemporal dementia: an open-label study</article-title>. <source>Drugs Aging</source>. <year>2004</year>;<volume>21</volume>(<issue>14</issue>):<fpage>931</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr97-1533317512467681">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shinotoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia</article-title>. <source>Brain</source>. <year>2010</year>;<volume>133</volume>(<issue>pt 7</issue>):<fpage>2058</fpage>–<lpage>2068</lpage>.</citation>
</ref>
<ref id="bibr98-1533317512467681">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CP</given-names>
</name>
</person-group>. <article-title>Dual action of memantine in Alzheimer disease: a hypothesis</article-title>. <source>Taiwan J Obstet Gynecol</source>. <year>2009</year>;<volume>48</volume>(<issue>3</issue>):<fpage>273</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr99-1533317512467681">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Coria</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Billings</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group> <article-title>Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice</article-title>. <source>Am J Pathol</source>. <year>2010</year>;<volume>176</volume>(<issue>2</issue>):<fpage>870</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr100-1533317512467681">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Womack</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2009</year>;<volume>23</volume>(<issue>3</issue>):<fpage>211</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr101-1533317512467681">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanberg</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Memantine for behavioral disturbances in frontotemporal dementia: a case series</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2007</year>;<volume>21</volume>(<issue>2</issue>):<fpage>164</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr102-1533317512467681">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diehl-Schmid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Forstl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Perneczky</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>A 6-month, open-label study of memantine in patients with frontotemporal dementia</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2008</year>;<volume>23</volume>(<issue>7</issue>):<fpage>754</fpage>–<lpage>759</lpage>.</citation>
</ref>
<ref id="bibr103-1533317512467681">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vercelletto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boutoleau-Bretonniere</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Volteau</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Memantine in behavioral variant frontotemporal dementia: negative results</article-title>. <source>J Alzheimers Dis</source>. <year>2011</year>;<volume>23</volume>(<issue>4</issue>):<fpage>749</fpage>–<lpage>759</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>